Continued treatment with Briumvi provided sustained clinical benefits to patients with relapsing MS, particularly when started earlier.

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said new biomarker data from an expanded-access program showed its experimental ...

"The observed differential effects of high-efficacy disease-modifying agents across sexes underscore the importance of sex-specific considerations in making treatment decisions to personalize care in ...

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

Real-world data show Ocrevus reduced relapse rates and maintained disability stability in relapsing MS over four years.

A generation ago, most people with multiple sclerosis could expect to rely on walkers and wheelchairs or be limited to their bed within 15 years of diagnosis. Today, UC San Francisco’s discoveries are ...

PARIS — The first real guidelines on the use of disease-modifying therapies in multiple sclerosis (MS) have been released by a European joint venture between the European Committee for Research and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. March is Multiple Sclerosis Awareness Month, a time to ...

Over 95% of the world's adult population is infected with Epstein-Barr virus (EBV), but most people never realize it. The infection often causes few symptoms and then stays in the body for life.

It helps align clinical practice and reimbursement pathways, ensuring that clinical decision-making and insurance coverage ...